

PRESS RELEASE

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options.

Today, the last trading day of the month, there are in total 65,985,480 shares and votes in Active Biotech.

Lund, October 29, 2010 Active Biotech AB (publ)

For further information, please contact:

Hans Kolam, CFO Tel: +46 (0)46 19 20 44 E-mail: hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDexTM for RA. Please visit <u>www.activebiotech.com</u> for more information.

Active Biotech AB PO Box 724, SE-220 07 Lund Sweden Tel: +46 (0)46-19 20 00 Fax: +46 (0)46-19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:30 a.m. CET on October 29, 2010.